TrialPanorama/TrialPanorama-database huggingface dataset:
Study: 9151591
Drug: Immediate implants
Normalized name: IR-3535
Approvals — FDA: no, EMA: no, PMDA: no
Description: Immediate implants without guided tissue regeneration (Control group 1)
Study: 9151591
Drug: Standard procedure
Normalized name: HOMOSALATE 60 mg in 1 mL / OCTOCRYLENE 30 mg in 1 mL / ZINC OXIDE 80 mg in 1 mL TOPICAL STICK [Standard Procedure Lip Balm SPF 50]
Approvals — FDA: no, EMA: no, PMDA: no
Description: Standard procedure implants (Control group 2)
Study: 1331020
Drug: Temafloxacin 600
Normalized name: temafloxacin 600 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Temafloxacin 600 mg every 12 h for 7-14 days
Study: 1331020
Drug: Ciprofloxacin 750
Normalized name: ciprofloxacin 750 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Ciprofloxacin 750 mg every 12 h for 7-14 days
Study: 22662602
Drug: Intravenous Ceftazidime
Normalized name: Ceftazidime
DrugBank: Ceftazidime (DB00438)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Intravenous Ceftazidime within 60 minutes prior to surgery
Study: 22662602
Drug: Intravenous placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Intravenous placebo (10 ml isotonic sodium chloride 0.9% solution)
Study: 18355134
Drug: Latanoprost 0.005%
Normalized name: LATANOPROST 0.005% SOLN,OPH
Approvals — FDA: no, EMA: no, PMDA: no
Description: Latanoprost 0.005% once-daily in the evening
Study: 18355134
Drug: Timolol maleate
Normalized name: Timolol Maleate
DrugBank: Timolol (DB00373)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Timolol maleate 0.5% in Gelrite once-daily in the morning
Study: 16918588
Drug: Metformin (500
Approvals — FDA: no, EMA: no, PMDA: no
Description: Metformin (500 mg) plus rosiglitazone (2 mg), administered as one capsule twice daily
Study: 10758071
Drug: Exposure therapy
Normalized name: Monistat Simple Therapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: Exposure therapy alone or in combination with sertraline
Study: 3883559
Drug: Intravenous fluid
Normalized name: Intravenous fluid
Approvals — FDA: no, EMA: no, PMDA: no
Description: Intravenous fluid regimen with 3.5% amino acids, 20% fat, and 2.5% glucose
Study: 3883559
Drug: Intravenous fluid
Normalized name: Intravenous fluid
Approvals — FDA: no, EMA: no, PMDA: no
Description: Intravenous fluid regimen with 3.5% amino acids and 20% fat alone
Study: 31790905
Drug: Lipid-lowering therapy
Normalized name: guggul lipids
Approvals — FDA: no, EMA: no, PMDA: no
Description: Lipid-lowering therapy (statins, ezetimibe)
Study: 31790905
Drug: Each 10
Normalized name: ClindaReach 10 MG/ML Medicated Pad
Approvals — FDA: no, EMA: no, PMDA: no
Description: Each 10 mg/dL higher LDL-C value
Study: 28481434
Drug: Lisdexamfetamine dimesylate
Normalized name: Lisdexamfetamine Dimesylate
DrugBank: Lisdexamfetamine (DB01255)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Lisdexamfetamine dimesylate (LDX) 50 or 70 mg
Study: 21319354
Drug: Propofol combined
Normalized name: Propofol
DrugBank: Propofol (DB00818)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Propofol combined with low dose fentanyl (PF group)
Study: 21319354
Drug: Midazolam combined
Normalized name: Midazolam
DrugBank: Midazolam (DB00683)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Midazolam combined with low dose fentanyl (MF group)
Study: 19101790
Drug: Combination of
Normalized name: combination of rauwolfia alkaloids and diuretics incl. other combinations
Approvals — FDA: no, EMA: no, PMDA: no
Description: Combination of targeted agents (specific agents not mentioned)
Study: 12596015
Drug: Interferon-beta 1a
Normalized name: interferon beta-1a
DrugBank: Interferon beta-1a (DB00060)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Interferon-beta 1a (44 microg subcutaneous Rebif once weekly)
Study: 10854087
Drug: Nifedipine GITS,
Approvals — FDA: no, EMA: no, PMDA: no
Description: Nifedipine GITS, 30 mg
Study: 10069685
Drug: Lacidipine, 4
Approvals — FDA: no, EMA: no, PMDA: no
Description: Lacidipine, 4 mg
Study: 9180716
Drug: Textured saline-filled
Approvals — FDA: no, EMA: no, PMDA: no
Description: Textured saline-filled implants
Study: 9180716
Drug: Smooth saline-filled
Approvals — FDA: no, EMA: no, PMDA: no
Description: Smooth saline-filled implants
Study: 1524921
Drug: Adjuvant tamoxifen
Approvals — FDA: no, EMA: no, PMDA: no
Description: Adjuvant tamoxifen daily for 2 years
Study: 22619366
Drug: 3 g
Normalized name: Molds 3 g
Approvals — FDA: no, EMA: no, PMDA: no
Description: 3 g of gluten/day
Study: 22619366
Drug: 7.5 g
Normalized name: glucose 15 GM per 37.5 GM Oral Gel
Approvals — FDA: no, EMA: no, PMDA: no
Description: 7.5 g of gluten/day
Study: 22619366
Drug: 3 g
Normalized name: Molds 3 g
Approvals — FDA: no, EMA: no, PMDA: no
Description: 3 g or 7.5 g of gluten/day
Study: 12817159
Drug: Paroxetine (10-60
Approvals — FDA: no, EMA: no, PMDA: no
Description: Paroxetine (10-60 mg/day)
Study: 8606209
Drug: Terbutaline 0.5
Approvals — FDA: no, EMA: no, PMDA: no
Description: Terbutaline 0.5 mg subcutaneously 6 hourly for 48 hours (group T)
Study: 7036765
Drug: Sulfadoxine-pyrimethamine in
Normalized name: pyrimethamine / sulfadoxine
Approvals — FDA: no, EMA: no, PMDA: no
Description: Sulfadoxine-pyrimethamine in combination with chloroquine
Study: 22278425
Drug: Medical treatment
Normalized name: Hongo Killer Treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: Medical treatment with pasireotide, cabergoline, and ketoconazole over 80 days
Study: 21125810
Drug: Test formulation
Normalized name: mumps skin test antigen
Approvals — FDA: no, EMA: no, PMDA: no
Description: Test formulation (250 mg alpha-methyldopa tablet)
Study: 21125810
Drug: Reference formulation
Approvals — FDA: no, EMA: no, PMDA: no
Description: Reference formulation (250 mg alpha-methyldopa tablet)
Study: 11908635
Drug: Bovine lactoferrin
Normalized name: Bovine lactoferrin
Approvals — FDA: no, EMA: no, PMDA: no
Description: Bovine lactoferrin (bLf) gargles (100 mg t.i.d.) + oral erythromycin (500 mg t.i.d.)
Study: 11908635
Drug: Oral erythromycin
Normalized name: Erythromycin
DrugBank: Erythromycin (DB00199)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Oral erythromycin (500 mg t.i.d.)
Study: 7744989
Drug: Combined therapy
Normalized name: REGN10933+REGN10987 combination therapy
DrugBank: Anti-SARS-CoV-2 REGN-COV2 (DB15691)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Combined therapy (methimazole and thyroxine)
Study: 28503781
Drug: Upadacitinib (3
Approvals — FDA: no, EMA: no, PMDA: no
Description: Upadacitinib (3 mg) after high-fat meal
Study: 28503781
Drug: Upadacitinib (3
Approvals — FDA: no, EMA: no, PMDA: no
Description: Upadacitinib (3 mg) with ketoconazole (400 mg once daily for 6 days)
Study: 28503781
Drug: Upadacitinib (12
Approvals — FDA: no, EMA: no, PMDA: no
Description: Upadacitinib (12 mg) with rifampin (600 mg once daily for 9 days)
Study: 28503781
Drug: Upadacitinib (12
Approvals — FDA: no, EMA: no, PMDA: no
Description: Upadacitinib (12 mg) with single dose of rifampin
Study: 21401909
Drug: Intravitreal injection
Normalized name: Eylea 2 MG per 0.05 ML Intravitreal Injection
Approvals — FDA: no, EMA: no, PMDA: no
Description: Intravitreal injection of 0.05 ml anti-vascular endothelial growth factor agents
Study: 9208536
Drug: Kuangquan 851
Approvals — FDA: no, EMA: no, PMDA: no
Description: Kuangquan 851 Oral Liquor type R
Study: 9208536
Drug: Kuangquan 851
Approvals — FDA: no, EMA: no, PMDA: no
Description: Kuangquan 851 Oral Liquor type Y
Study: 9208536
Drug: Qing Chun
Normalized name: qing feng teng stem extract
Approvals — FDA: no, EMA: no, PMDA: no
Description: Qing Chun Bao Oral Liquor
Study: 1339081
Drug: 10 g
Normalized name: Co Q-10 Gummies
Approvals — FDA: no, EMA: no, PMDA: no
Description: 10 g fiber as wheat bran (WB)
Study: 1339081
Drug: 30 g
Normalized name: Lancet Unilet 30 g
Approvals — FDA: no, EMA: no, PMDA: no
Description: 30 g fiber as wheat bran (WB)
Study: 1339081
Drug: 10 g
Normalized name: Co Q-10 Gummies
Approvals — FDA: no, EMA: no, PMDA: no
Description: 10 g fiber as vegetable fiber (VF)
Study: 1339081
Drug: 30 g
Normalized name: Lancet Unilet 30 g
Approvals — FDA: no, EMA: no, PMDA: no
Description: 30 g fiber as vegetable fiber (VF)
Study: 31788819
Drug: Verbal feedback
Normalized name: HERBAL MISCELLANEOUS
Approvals — FDA: no, EMA: no, PMDA: no
Description: Verbal feedback on performance during meal preparation sessions with an occupational therapist
Study: 31788819
Drug: Experiential feedback
Approvals — FDA: no, EMA: no, PMDA: no
Description: Experiential feedback only (control condition) during meal preparation sessions
Study: 20496094
Drug: 64 MDCT
Approvals — FDA: no, EMA: no, PMDA: no
Description: 64 MDCT scans performed with oral and intravenous contrast
Study: 20496094
Drug: 64 MDCT
Approvals — FDA: no, EMA: no, PMDA: no
Description: 64 MDCT scans performed solely with intravenous contrast
Study: 18206918
Drug: Tamsulosin hydrochloride
Normalized name: Tamsulosin Hydrochloride
DrugBank: Tamsulosin (DB00706)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Tamsulosin hydrochloride 0.2 mg daily for 12 weeks
Study: 18206918
Drug: Naftopidil 50
Normalized name: Naftopidil
DrugBank: Naftopidil (DB12092)
Approvals — FDA: no, EMA: no, PMDA: yes
Description: Naftopidil 50 mg daily for 12 weeks
Study: 14556878
Drug: Glycoprotein IIb/IIIa
Normalized name: GLYCOPROTEIN IIB/IIIA
Approvals — FDA: no, EMA: no, PMDA: no
Description: Glycoprotein IIb/IIIa inhibitors after initial coronary angiography
Study: 10950233
Drug: Inhaled fluticasone
Normalized name: fluticasone Inhalant Product
Approvals — FDA: no, EMA: no, PMDA: no
Description: Inhaled fluticasone propionate (1000 microg daily for 7 days)
Study: 10950233
Drug: Intravenous fluticasone
Approvals — FDA: no, EMA: no, PMDA: no
Description: Intravenous fluticasone propionate (1000 microg)
Study: 8643221
Drug: Methotrexate (MTX)
Normalized name: Methotrexate
DrugBank: Methotrexate (DB00563)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Methotrexate (MTX) 250 mg/m2, followed by L-folinic acid (LFA) 250 mg/m2 and 5-fluorouracil (FU) 600 mg/m2
Study: 8643221
Drug: Methotrexate (MTX)
Normalized name: Methotrexate
DrugBank: Methotrexate (DB00563)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Methotrexate (MTX) 500 mg/m2, followed by L-folinic acid (LFA) 250 mg/m2 and 5-fluorouracil (FU) 600 mg/m2
Study: 6382640
Drug: Short-course chemotherapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: Short-course chemotherapy for silicotuberculosis
Study: 19841156
Drug: Escitalopram 5,
Approvals — FDA: no, EMA: no, PMDA: no
Description: Escitalopram 5, 10, 15, or 20 mg daily for a minimum of 32 weeks
Study: 18633463
Drug: Oral-B Vitality
Normalized name: Vital-Chlor
Approvals — FDA: no, EMA: no, PMDA: no
Description: Oral-B Vitality Pro White power toothbrush
Study: 8803304
Drug: Paroxetine (20
Approvals — FDA: no, EMA: no, PMDA: no
Description: Paroxetine (20 to 30 mg/day)
Study: 8803304
Drug: Imipramine (100
Approvals — FDA: no, EMA: no, PMDA: no
Description: Imipramine (100 to 125 mg/day)
Study: 1376306
Drug: Induction chemotherapy
Normalized name: human sputum, Bordetella pertussis infected
Approvals — FDA: no, EMA: no, PMDA: no
Description: Induction chemotherapy (bleomycin 10 mg/m2/day, methotrexate 120 mg/m2, folinic acid, 5-fluorouracil 600 mg/m2, cisplatin 120 mg/m2)
Study: 1376306
Drug: Locoregional treatment
Normalized name: Hongo Killer Treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: Locoregional treatment alone (control group)
Study: 3934685
Drug: Intravenous pindolol
Normalized name: Pindolol
DrugBank: Pindolol (DB00960)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Intravenous pindolol (0.0256 mg/kg)
Study: 30644999
Drug: Nurse-led decentralized
Normalized name: ethanol
DrugBank: Ethanol (DB00898)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Nurse-led decentralized ART treatment program
Study: 30644999
Drug: Combination of
Normalized name: combination of rauwolfia alkaloids and diuretics incl. other combinations
Approvals — FDA: no, EMA: no, PMDA: no
Description: Combination of nurse-led decentralized ART and individualized case management
Study: 25328284
Drug: Inhaled nitric
Normalized name: nitric oxide Inhalant Product
Approvals — FDA: no, EMA: no, PMDA: no
Description: Inhaled nitric oxide (iNO) 80 ppm throughout the operation
Study: 25328284
Drug: Inhaled nitric
Normalized name: nitric oxide Inhalant Product
Approvals — FDA: no, EMA: no, PMDA: no
Description: Inhaled nitric oxide (iNO) at the beginning and end of the operation
Study: 20828223
Drug: Bedtime administration
Normalized name: Buckley's Bedtime Formula
Approvals — FDA: no, EMA: no, PMDA: no
Description: Bedtime administration of amlodipine-olmesartan
Study: 20828223
Drug: Morning administration
Approvals — FDA: no, EMA: no, PMDA: no
Description: Morning administration of amlodipine-olmesartan
Study: 7562763
Drug: Group physical
Normalized name: Streptococcus viridans group
Approvals — FDA: no, EMA: no, PMDA: no
Description: Group physical therapy (weekly sessions)
Study: 7966073
Drug: Daily exercises
Approvals — FDA: no, EMA: no, PMDA: no
Description: Daily exercises at home
Study: 1976580
Drug: Combined administration
Approvals — FDA: no, EMA: no, PMDA: no
Description: Combined administration of 150 mg of roxatidine and 50 mg of pirenzepine
Study: 1976580
Drug: 150 mg
Normalized name: pectin 150 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 150 mg of roxatidine
Study: 7387018
Drug: High-dose theophylline
Approvals — FDA: no, EMA: no, PMDA: no
Description: High-dose theophylline (17 to 22 micrograms/mL)
Study: 7387018
Drug: Low-dose theophylline
Normalized name: ethinyl estradiol
DrugBank: Ethinylestradiol (DB00977)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Low-dose theophylline (9.0 to 12.5 micrograms/mL)
Study: 21107937
Drug: Intrathecal infusion
Normalized name: Duo Fusion
DrugBank: Magnesium hydroxide (DB09104)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Intrathecal infusion of morphine
Study: 11679925
Drug: Low-, medium-,
Approvals — FDA: no, EMA: no, PMDA: no
Description: Low-, medium-, or high-dose recombinant gp120 vaccine with MF59 adjuvant
Study: 11679925
Drug: Accelerated vaccine
Normalized name: Pertussis vaccine
DrugBank: Pertussis vaccine (DB15274)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Accelerated vaccine schedule (birth and ages 2, 8, and 20 weeks) with defined optimal dose
Study: 8135449
Drug: Sucralfate, 1
Normalized name: Sucralfate, 1 g oral tablet
Approvals — FDA: no, EMA: no, PMDA: no
Description: Sucralfate, 1 g every 4 hours
Study: 8135449
Drug: Antacid (aluminum
Normalized name: Antacid (Aluminum-Magnesium)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Antacid (aluminum hydroxide and magnesium hydroxide), 20 mL every 2 hours
Study: 8135449
Drug: Ranitidine, 150
Approvals — FDA: no, EMA: no, PMDA: no
Description: Ranitidine, 150 mg as a continuous intravenous infusion
Study: 2644391
Drug: 2-g single
Approvals — FDA: no, EMA: no, PMDA: no
Description: 2-g single dose of metronidazole for male partners
Study: 2644391
Drug: Seven-day course
Normalized name: Sevenfact
DrugBank: Coagulation factor VIIa Recombinant Human (DB00036)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Seven-day course of 500 mg metronidazole twice a day
Study: 2644391
Drug: Single-dose metronidazole
Normalized name: Metronidazole
DrugBank: Metronidazole (DB00916)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Single-dose metronidazole
Study: 1261583
Drug: Practolol (0.1
Approvals — FDA: no, EMA: no, PMDA: no
Description: Practolol (0.1 mg/kg i.v.)
Study: 1261583
Drug: Combination of
Normalized name: combination of rauwolfia alkaloids and diuretics incl. other combinations
Approvals — FDA: no, EMA: no, PMDA: no
Description: Combination of practolol and verapamil (0.1 mg/kg i.v.)
Study: 1261583
Drug: Combination of
Normalized name: combination of rauwolfia alkaloids and diuretics incl. other combinations
Approvals — FDA: no, EMA: no, PMDA: no
Description: Combination of practolol and verapamil (practolol preceding verapamil)
Study: 27899754
Drug: Anodal transcranial
Approvals — FDA: no, EMA: no, PMDA: no
Description: Anodal transcranial direct current stimulation combined with constraint-induced movement therapy
Study: 27899754
Drug: Sham transcranial
Approvals — FDA: no, EMA: no, PMDA: no
Description: Sham transcranial direct current stimulation combined with constraint-induced movement therapy
Study: 17724283
Drug: ZNS 5
Normalized name: GLYCERIN 0.25 g in 5 mL TOPICAL SOLUTION [ZNSP Ampoule]
Approvals — FDA: no, EMA: no, PMDA: no
Description: ZNS 5 mg
Study: 17724283
Drug: ZNS 10
Normalized name: GLYCERIN 0.16 g in 8 g TOPICAL CREAM [ZNSP Repair]
Approvals — FDA: no, EMA: no, PMDA: no
Description: ZNS 10 mg
Study: 15134386
Drug: Chondroitin sulfate
Normalized name: Chondroitin Sulfate
DrugBank: Chondroitin sulfate (DB09301)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Chondroitin sulfate (CHS) 800 mg orally plus naproxen 500 mg
Study: 15134386
Drug: Naproxen 500
Normalized name: naproxen 500 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Naproxen 500 mg only
Study: 12482765
Drug: Propranolol (100
Approvals — FDA: no, EMA: no, PMDA: no
Description: Propranolol (100 mg/day for 5 days)
Study: 9680769
Drug: 5% salicylic
Normalized name: salicylic acid 285 mg in 1 mL TOPICAL SOLUTION [28.5% Salicylic Acid]
Approvals — FDA: no, EMA: no, PMDA: no
Description: 5% salicylic acid and 10% urea ointment (Kerasal)
Study: 9680769
Drug: 12% ammonium
Approvals — FDA: no, EMA: no, PMDA: no
Description: 12% ammonium lactate lotion (Lac‐Hydrin)
Study: 23903014
Drug: Donor stem
Normalized name: stem bromelain
DrugBank: Stem bromelain (DB12249)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Donor stem cell infusion (DSCI)
Study: 21913140
Drug: Carbohydrate solution
Normalized name: phosphorated carbohydrate solution
Approvals — FDA: no, EMA: no, PMDA: no
Description: Carbohydrate solution (3 ml · kg (‐1) body weight)
Study: 18312401
Drug: GW406381 (70
Approvals — FDA: no, EMA: no, PMDA: no
Description: GW406381 (70 mg)
Study: 18312401
Drug: naproxen sodium
Normalized name: Naproxen Sodium
DrugBank: Naproxen (DB00788)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: naproxen sodium (825 mg)
Study: 17060219
Drug: Two commonly
Approvals — FDA: no, EMA: no, PMDA: no
Description: Two commonly used treatments for liquid aspiration
Study: 10666521
Drug: Epidural morphine
Approvals — FDA: no, EMA: no, PMDA: no
Description: Epidural morphine preemptively before surgery and maintained until skin closure
Study: 10666521
Drug: Epidural morphine
Approvals — FDA: no, EMA: no, PMDA: no
Description: Epidural morphine post-surgery via PCA pump
Study: 2462651
Drug: Various treatment
Normalized name: Hongo Killer Treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: Various treatment subgroups
Study: 25377507
Drug: ramucirumab (10
Approvals — FDA: no, EMA: no, PMDA: no
Description: ramucirumab (10 mg/kg) plus pemetrexed and carboplatin (or cisplatin)
Study: 14520769
Drug: Diclofenac-K (12.5
Approvals — FDA: no, EMA: no, PMDA: no
Description: Diclofenac-K (12.5 mg)
Study: 10716135
Drug: valsartan 80
Normalized name: valsartan 80 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: valsartan 80 mg once daily
Study: 1283198
Drug: Spinal anesthesia
Normalized name: Bos taurus spinal cord preparation
Approvals — FDA: no, EMA: no, PMDA: no
Description: Spinal anesthesia with 8 ml bupivacaine 0.5% + 5 ml lignocaine 2%
Study: 3087550
Drug: Subcutaneous estradiol
Normalized name: Estradiol
DrugBank: Estradiol acetate (DB13952)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Subcutaneous estradiol implants combined with cyclical oral norethisterone
Study: 29802443
Drug: Low-dose X-82
Normalized name: ethinyl estradiol
DrugBank: Ethinylestradiol (DB00977)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Low-dose X-82 (200 mg)
Study: 29802443
Drug: High-dose X-82
Approvals — FDA: no, EMA: no, PMDA: no
Description: High-dose X-82 (400 mg)
Study: 24524389
Drug: Oral antibiotics
Approvals — FDA: no, EMA: no, PMDA: no
Description: Oral antibiotics (Group B)
Study: 24524389
Drug: Neither probiotics
Normalized name: Rezyst Probiotic
Approvals — FDA: no, EMA: no, PMDA: no
Description: Neither probiotics nor oral antibiotics (Group C)
Study: 18848381
Drug: Fluoxetine (20mg
Approvals — FDA: no, EMA: no, PMDA: no
Description: Fluoxetine (20mg daily for 90 days)
Study: 18848381
Drug: Cognitive Behavior
Normalized name: Mahana Parallel Digital Cognitive Behavioral Therapy Mobile Application for Irritable Bowel Syndrome
Approvals — FDA: no, EMA: no, PMDA: no
Description: Cognitive Behavior Therapy (10 sessions)
Study: 10596917
Drug: Dacarbazine (DTIC)
Normalized name: Dacarbazine
DrugBank: Dacarbazine (DB00851)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Dacarbazine (DTIC) 800 mg/m2 every 21 days, IL-2 9 MIU subcutaneously days 1-5 and 8-12, interferon 3 MU subcutaneously three times a week, tamoxifen 20 mg orally throughout
Study: 10596917
Drug: Cisplatin 30
Normalized name: Cisplatin
DrugBank: Cisplatin (DB00515)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Cisplatin 30 mg/m2 days 1-3, DTIC 250 mg/m2 days 1-3, vindesine 2.5 mg/m2 day 1 every 28 days, interferon 3 MU subcutaneously three times a week, tamoxifen 20 mg orally throughout
Study: 10596917
Drug: Cisplatin, DTIC,
Approvals — FDA: no, EMA: no, PMDA: no
Description: Cisplatin, DTIC, vindesine (CVD) plus IL-2 6 MIU days 1-5 and 8-12 every 28 days, interferon 3 MU subcutaneously three times a week, tamoxifen 20 mg orally throughout
Study: 8992424
Drug: Etoposide (100
Approvals — FDA: no, EMA: no, PMDA: no
Description: Etoposide (100 mg/m2/1h) administered immediately before and at the end (24th h) of methotrexate treatment
Study: 8992424
Drug: Etoposide (100
Approvals — FDA: no, EMA: no, PMDA: no
Description: Etoposide (100 mg/m2/1h) administered at 24 h and at 48 h after starting methotrexate infusion
Study: 7105823
Drug: Film-coated indoramin
Normalized name: indoramin
DrugBank: Indoramin (DB08950)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Film-coated indoramin (50 mg tablets)
Study: 7105823
Drug: Uncoated indoramin
Normalized name: indoramin
DrugBank: Indoramin (DB08950)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Uncoated indoramin (50 mg tablets)
Study: 7105823
Drug: Film-coated indoramin
Normalized name: indoramin
DrugBank: Indoramin (DB08950)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Film-coated indoramin (2 tablets)
Study: 26265232
Drug: PH‐797804 30
Approvals — FDA: no, EMA: no, PMDA: no
Description: PH‐797804 30 mg (oral)
Study: 26265232
Drug: PF‐03715455 20
Approvals — FDA: no, EMA: no, PMDA: no
Description: PF‐03715455 20 mg (inhaled)
Study: 26265232
Drug: Fluticasone propionate
Normalized name: Fluticasone Propionate
DrugBank: Fluticasone propionate (DB00588)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: Fluticasone propionate 500 μg (inhaled)
Study: 22081122
Drug: Traditional logopedic
Normalized name: sodium fluoride
DrugBank: Sodium fluoride (DB09325)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Traditional logopedic dysphagia treatment
Study: 22081122
Drug: Traditional logopedic
Normalized name: sodium fluoride
DrugBank: Sodium fluoride (DB09325)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Traditional logopedic dysphagia treatment combined with NMES at sensor or motor level stimulation
Study: 20815879
Drug: A-L dispersible
Normalized name: ethylcellulose aqueous dispersion type A
Approvals — FDA: no, EMA: no, PMDA: no
Description: A-L dispersible tablet (cherry flavour)
Study: 20815879
Drug: A-L dispersible
Normalized name: ethylcellulose aqueous dispersion type A
Approvals — FDA: no, EMA: no, PMDA: no
Description: A-L dispersible tablet (80 mg artemether + 480 mg lumefantrine)
Study: 20815879
Drug: A-L dispersible
Normalized name: ethylcellulose aqueous dispersion type A
Approvals — FDA: no, EMA: no, PMDA: no
Description: A-L dispersible tablet
Study: 17132823
Drug: GH (2
Normalized name: Somatropin
DrugBank: Somatotropin (DB00052)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: GH (2 mg daily)